Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

January 11, 2017

Adamas Completes Phase 1 Study of Therapy for Partial Onset Epilepsy Seizures

News

Adamas Pharmaceuticals has completed a Phase 1 clinical trial evaluating its drug candidate ADS-4101 to treat partial onset seizures in patients with epilepsy. “We are encouraged by the results of this ... Read more

January 6, 2017

European Agency Favors Votubia as Adjunct Therapy for Seizures Related to TSC

News

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’ Votubia (everolimus) dispersible tablets as an adjunctive therapy for patients, ages 2 ... Read more

December 7, 2016

GW Pharmaceuticals Presents Positive Results of Cannabidiol Epidiolex at Epilepsy Confab

News

GW Pharmaceuticals recently presented positive results from two Phase 3 clinical trials evaluating its lead cannabidiol therapeutic candidate, Epidiolex, in patients with lennox-gastaut syndrome (LGS) and Dravet syndrome (DS), two treatment-resistant ... Read more

November 9, 2016

Adherence to Medication Regimen Not Influenced by Doctors’ Reminders

News

Among patients with epilepsy, addressing the side effects of anti-seizure medications at every doctor’s visit does not increase patients’ adherence to their medications. That said, researchers emphasize the assessment of ... Read more

November 7, 2016November 7, 2016

Epilepsy Treatment, Sodium Valproate, Can Harm Unborn Child, UK Group Warns

News

The Epilepsy Society in the U.K. reported that the Academic of Medical Royal Colleges (AMRC) is advising doctors not to prescribe sodium valproate to women with epilepsy who are of childbearing age or ... Read more

October 19, 2016

TSC Infants at Risk of Seizures to Be Treated with Sabril as Preventive Measure in Study

News

The University of Alabama at Birmingham (UAB) is leading a multi-site clinical trial, the first investigating the impact of the antiepileptic drug Sabril (vigabatrin) in preventing or delaying the onset of epilepsy ... Read more

October 17, 2016

Epilepsy Foundation, CDC Team Up to Raise Awareness About Epilepsy

News

The Epilepsy Foundation has entered into a $16 million agreement with the Centers for Disease Control and Prevention (CDC) to improve education and awareness of epilepsy. The five-year initiative is part ... Read more

October 12, 2016October 12, 2016

FDA Approves Carnexiv Injection as Replacement Therapy for Seizure Control

News

The U.S. Food and Drug Administration (FDA) has approved the anti-epileptic drug Carnexiv (carbamazepine) injection for adults with certain seizure types, announced Lundbeck, the drug’s global pharmaceutical company. The new indication of carbamazepine ... Read more

September 21, 2016

Epilepsy Foundation Launches SUDEP Awareness and Seizure Control Campaign

News

Sudden Unexpected Death in Epilepsy (SUDEP) refers to a person with epilepsy dying suddenly and prematurely with no other cause of death found. However, educating people with epilepsy and their caregivers might reduce the risk of ... Read more

September 19, 2016September 26, 2016

Omega-3 Supplements for Drug-resistant Epilepsy Requires More Investigation, Review Suggests

News

The benefits of omega-3 supplements in people with drug-resistant epilepsy require additional investigation, according to a literature review conducted by researchers in Brazil. The report, “Polyunsaturated fatty acid supplementation for drug-resistant epilepsy,” was published in Cochrane ... Read more